 Bank of America began coverage on shares of Coherus Biosciences NASDAQ:CHRS in a research note issued to investors on Thursday morning, Benzinga reports. The firm issued a neutral rating and a 20.00 target price on the biotechnology companys stock. Other equities research analysts also recently issued research reports about the stock. Maxim Group initiated coverage ... 